XETRA - Delayed Quote • EUR Galapagos NV (GXE.DE) Follow 44.47 0.00 (0.00%) At close: October 21 at 5:35 PM GMT+2 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for GXE.DE 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: GXE.DE View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board Galapagos announces full year 2023 results and outlook for 2024 Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline Galapagos presents at EBMT-EHA annual meeting 2024 Galapagos completes transaction to transfer Jyseleca® business to Alfasigma Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S. Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets Galapagos signs agreement to transfer Jyseleca® business to Alfasigma Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
